Avalo Therapeutics logo
Avalo Therapeutics
AVTX | NASDAQ
Chart Builder DCF Calculator
$7.37
-$0.39 (-5.03%)
At close: Nov 16, 2026, 4:00 PM ET
$7.23
-$0.14 (-1.90%)
After-hours: Nov 16, 2026, 7:30 PM ET

Avalo Therapeutics Company Profile

Company profile explained

Company Profile

Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis. Furthermore, AVTX-002 is also being investigated in Phase III for its potential to treat acute respiratory distress syndrome caused by COVID-19. The company is also advancing AVTX-007, a fully human monoclonal antibody targeting IL-18, which is progressing through Phase I clinical studies for Still's disease, encompassing both adult-onset Still's disease and systemic juvenile idiopathic arthritis. Avalo's late-stage pipeline includes two products addressing rare genetic conditions, both in Phase III clinical trials: AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, an L-fucose substrate replacement therapy intended for LADII, medically referred to as SLC35C1-CDG. Established in 2011, the corporation initially operated as Cerecor Inc. before rebranding as Avalo Therapeutics, Inc. in August 2021. Its main operations are situated in Rockville, Maryland.

Key Executives

Name Position
Garry A. Neil President, Chief Executive Officer & Director
Christopher Ryan Sullivan Chief Financial Officer & Head of Investor relations
Paul C. Varki Chief Legal Officer
Ashley Ivanowicz Senior Vice President of Human Resources
Barbara S. Slusher Founder and Member of Scientific Advisory Board
Dino C. Miano Senior Vice President of CMC & Technical Operations
Jennifer Riley Chief Strategy Officer
Mittie Doyle FACR Chief Medical Officer
Solomon H. Snyder Founder and Chairman of Scientific Advisory Board
Taylor Boyd Chief Business Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 18, 2026 4 Filing
Sep 11, 2026 4 Filing
Sep 01, 2026 4 Filing
Aug 19, 2026 4 Filing
Aug 19, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
View All SEC Filings ➞
Avalo Therapeutics
Avalo Therapeutics logo
Country United States
IPO Date Oct 14, 2015
Industry Biotechnology
Sector Healthcare
Employees 33
CEO Garry A. Neil

Contact Details

1500 Liberty Ridge Drive Wayne, Pennsylvania 19087 United States

Stock Details

Ticker Symbol AVTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001534120
CUSIP Number 05338F306
ISIN Number US05338F3064
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.